Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

From ‘Ozempic face’ to ‘Ozempic fingers’ and even ‘Wegovy butt,’ the potential side effects of weight loss medications have ...

Now, alarmed by sunken features and sagging skin, newly svelte patients are flooding med spas and plastic surgery clinics, desperate to plump, lift and smooth their way back to a youthful glow. These ...

Weight loss medications like Wegovy and Zepbound are gaining popularity as millions turn to them for quick results and potential health benefits.

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly ( LLY 3.84%) and Novo Nordisk ( NVO 2.01%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...